Chenodeoxycholic Acid (CAS 474-25-9): Complete Guide to This Primary Bile Acid for Gallstone Treatment
Введение
Chenodeoxycholic acid (also known as chenodiol) is a primary bile acid that plays a crucial role in human metabolism and has been used medically for decades to treat cholesterol gallstones. With the CAS number 474-25-9, this compound is one of the two primary bile acids produced by the human liver and has garnered significant attention in gastroenterology for its therapeutic applications.
This comprehensive guide explores the chemical properties, mechanisms of action, clinical applications, safety considerations, and market significance of Chenodeoxycholic Acid.
What is Chenodeoxycholic Acid?
Chenodeoxycholic acid is a primary bile acid with the molecular formula C24H40O4 and a molecular weight of 392.57 g/mol. It is one of the two main primary bile acids in humans, with the other being cholic acid. Originally discovered and isolated from bird droppings (particularly from chickens and other birds), chenodeoxycholic acid is now synthesized commercially for pharmaceutical applications.
Химические свойства
- CAS Number: 474-25-9
- Молекулярная формула: C24H40O4
- Molecular Weight: 392.57 g/mol
- Внешний вид: Белый кристаллический порошок
- Температура плавления: 165-167°C
- Растворимость: Soluble in alcohol, chloroform, and dilute alkali solutions
Классификация
- Type: Primary bile acid
- Category: API (Active Pharmaceutical Ingredient) / Food Additives
Natural Sources and Biosynthesis
Chenodeoxycholic acid is synthesized in the human liver from cholesterol through a complex biochemical pathway involving multiple enzymatic reactions. The process, known as the bile acid synthesis pathway, involves approximately 17 different enzymes and represents a major route for cholesterol elimination from the body.
In nature, chenodeoxycholic acid can be found in:
- Human bile: Approximately 30-40% of total bile acid pool
- Bird droppings: Historically the main source for commercial extraction
- Animal bile: Particularly from chickens, ducks, and other poultry
Today, commercial production primarily relies on chemical synthesis to ensure purity and consistent quality for pharmaceutical applications.
Механизм действия
The therapeutic action of chenodeoxycholic acid in treating cholesterol gallstones is based on its ability to reduce cholesterol saturation in bile. Here is how it works:
1. Cholesterol Reduction in Bile
Chenodeoxycholic acid acts by:
- Suppressing hepatic synthesis of cholesterol
- Reducing cholesterol secretion into bile
- Increasing the proportion of bile acids in bile
2. Gallstone Dissolution
When bile becomes unsaturated with cholesterol, existing cholesterol gallstones can gradually dissolve. The process typically requires:
- 4-24 months of continuous treatment
- Functioning gallbladder
- Radiolucent (non-calcified) cholesterol stones smaller than 20mm
3. Metabolic Effects
Beyond gallstone treatment, chenodeoxycholic acid also:
- Stimulates bile flow
- Enhances intestinal absorption of dietary fats
- Modulates gut microbiome composition
Clinical Applications and Uses
1. Primary Indication: Cholesterol Gallstone Dissolution
The main therapeutic use of chenodeoxycholic acid is for the medical treatment of cholesterol gallstones. This treatment is particularly suitable for:
- Patients with small cholesterol stones (less than 20mm in diameter)
- Patients with functioning gallbladder
- Patients who are poor candidates for surgery
- Patients refusing surgery
- As an adjunct to lithotripsy (stone-breaking procedures)
2. Cerebrotendinous Xanthomatosis (CTX)
Chenodeoxycholic acid is also used to treat cerebrotendinous xanthomatosis, a rare genetic disorder characterized by:
- Abnormal cholesterol accumulation in tendons and brain
- Neurological dysfunction
- Premature cataracts
3. Biliary Secretion Disorders
The compound is sometimes used in research and clinical settings to study bile secretion disorders and liver function.
4. Research Applications
In laboratory settings, chenodeoxycholic acid is used as:
- Cholesterol-lowering agent in research
- Standard reference compound in bile acid analysis
- Tool compound in metabolic research
Benefits and Efficacy
Gallstone Dissolution Success Rates
Clinical studies have demonstrated that chenodeoxycholic acid can achieve complete gallstone dissolution in:
- 50-60% of patients with suitable stones
- Up to 80% when combined with ursodeoxycholic acid
- Typically requires 6-24 months of treatment
Key Advantages
- Non-invasive treatment option – Avoids surgical risks
- Effective for small cholesterol stones
- Can be used in high-risk patients
- Relatively low cost compared to surgery
- No recovery time required
Safety and Side Effects
Common Side Effects
The most frequently reported side effects include:
- Diarrhea: Most common, often dose-related
- Abdominal discomfort: Mild to moderate abdominal pain
- Nausea: Generally mild and transient
- Elevated liver enzymes: Transient transaminase elevations in up to 30% of patients
Rare but Serious Effects
- Clinically apparent liver injury (very rare)
- Pancreatitis (extremely rare)
Contraindications
- Pregnancy (Category X)
- Chronic liver disease
- Complete biliary obstruction
- Known hypersensitivity to bile acids
Drug Interactions
Chenodeoxycholic acid may interact with:
- Cholestyramine (reduces absorption)
- Oral contraceptives
- Certain cholesterol-lowering medications
Дозировка и применение
Standard Dosing
- Adult dose: 15 mg/kg/day divided into 2-3 doses
- Maximum dose: 1,000 mg per day
- Duration: 6-24 months or until stone dissolution
Treatment Guidelines
- Initial evaluation with ultrasound to confirm stone characteristics
- Baseline liver function tests
- Regular monitoring during treatment (every 6 months)
- Continued treatment for 3-6 months after stone dissolution to prevent recurrence
Chemical Specifications
| Property | Технические характеристики |
| Номер CAS | 474-25-9 |
| Молекулярная формула | C24H40O4 |
| Молекулярная масса | 392.57 g/mol |
| Внешний вид | Белый кристаллический порошок |
| Температура плавления | 165-167°C |
| Чистота | ≥98% (pharmaceutical grade) |
| Растворимость | Soluble in alcohol, chloroform |
| Хранение | Room temperature, protected from light |
Market Significance
Global Market Drivers
- Rising gallstone prevalence: Increasing incidence due to westernized diets and obesity
- Aging population: Higher risk of gallstones in older adults
- **Non-invasive treatment demand: Patient preference for conservative management
- Rare disease applications: Growing recognition of CTX and related disorders
Competitive Landscape
Chenodeoxycholic acid competes with:
- Ursodeoxycholic acid (more commonly prescribed)
- Surgical options (laparoscopic cholecystectomy)
- Extracorporeal shock wave lithotripsy
Заключение
Chenodeoxycholic Acid (CAS 474-25-9) remains an important therapeutic agent in the management of cholesterol gallstones and certain metabolic disorders. While surgical removal of the gallbladder remains the gold standard for symptomatic gallstone disease, chenodeoxycholic acid offers a valuable non-invasive alternative for appropriate candidates.
Its mechanism of action through cholesterol saturation reduction in bile makes it particularly effective for small, non-calcified cholesterol stones. As research continues into its broader metabolic effects and applications, chenodeoxycholic acid will likely maintain its place in gastroenterological therapy.
Keywords: Chenodeoxycholic Acid, CAS 474-25-9, gallstones, bile acid, chenodiol, cholesterol gallstones, medical treatment, cerebrotendinous xanthomatosis